IFNA1 and COVID-19: However, late administration of IFN-α or β (i.e., more than 10 days since COVID-19 diagnosis) resulted in poor prognosis of the disease in contrast to early therapy suggesting pathologic effect at advanced, inflammatory stage of COVID-19 [127,128].